Health
FDA revokes EUA for monoclonal antibody therapy bamlanivimab to treat patients with COVID-19 – News-Medical.Net
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab,…
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment…
-
Noosa News21 hours agoThis 42-Kilometre Walking Trail on the NSW North Coast Weaves Through Ancient Rainforest, Volcanic Mountains and Spectacular Waterfalls
-
Noosa News23 hours agoJane Bunn weather: Cyclone Errol forms as effects of Alfred still felt across Queensland
-
Noosa News22 hours agoGabby Petito died after experiencing domestic violence. Young Aussies are identifying with her story
-
General23 hours agoNo ‘band-aid solution’: sweating coal risky business